Cargando…

Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells

SIMPLE SUMMARY: Triple negative breast cancer is a disease with limited treatment options and the poorest outcome across all breast cancer subtypes, thus the need for new effective therapies is high. We recently found that navitoclax displays synergistic anti-proliferative and apoptotic activities w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marczyk, Michal, Patwardhan, Gauri A., Zhao, Jun, Qu, Rihao, Li, Xiaotong, Wali, Vikram B., Gupta, Abhishek K., Pillai, Manoj M., Kluger, Yuval, Yan, Qin, Hatzis, Christos, Pusztai, Lajos, Gunasekharan, Vignesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563413/ https://www.ncbi.nlm.nih.gov/pubmed/32911681 http://dx.doi.org/10.3390/cancers12092551

Ejemplares similares

Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations
por: Patwardhan, Gauri A., et al.
Publicado: (2021)

Evaluation of zero counts to better understand the discrepancies between bulk and single-cell RNA-Seq platforms
por: Zyla, Joanna, et al.
Publicado: (2023)

Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer
por: Wali, Vikram B., et al.
Publicado: (2019)

Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer
por: Jiang, Tingting, et al.
Publicado: (2014)

Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer
por: Marczyk, Michal, et al.
Publicado: (2022)

Germline variant burden in cancer genes correlates with age at diagnosis and somatic mutation burden
por: Qing, Tao, et al.
Publicado: (2020)

Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade
por: Casadevall, David, et al.
Publicado: (2019)

Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis
por: Jiang, Tingting, et al.
Publicado: (2016)

The Role of Navitoclax in Myelofibrosis
por: Pandravada, Sasirekha, et al.
Publicado: (2021)

Functional polymorphisms in cancer
por: Agarwal, Divyansh, et al.
Publicado: (2015)

Network propagation-based prioritization of long tail genes in 17 cancer types
por: Mohsen, Hussein, et al.
Publicado: (2021)

Increased epigenetic age in normal breast tissue from luminal breast cancer patients
por: Hofstatter, Erin W., et al.
Publicado: (2018)

Characterization of DNA variants in the human kinome in breast cancer
por: Agarwal, Divyansh, et al.
Publicado: (2015)

The Combination of Radiation with PARP Inhibition Enhances Senescence and Sensitivity to the Senolytic, Navitoclax, in Triple Negative Breast Tumor Cells
por: Softah, Abrar, et al.
Publicado: (2023)

Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers
por: O’Meara, Tess, et al.
Publicado: (2020)

Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial
por: Li, Xiaotong, et al.
Publicado: (2019)

The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues
por: Marczyk, Michal, et al.
Publicado: (2019)

An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes
por: Győrffy, Balázs, et al.
Publicado: (2018)

Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity
por: Shi, Weiwei, et al.
Publicado: (2018)

SIMVI reveals intrinsic and spatial-induced states in spatial omics data
por: Dong, Mingze, et al.
Publicado: (2023)

Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax
por: Ackler, Scott, et al.
Publicado: (2015)

Functional germline variants as potential co-oncogenes
por: Agarwal, Divyansh, et al.
Publicado: (2017)

Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer
por: Zoeller, Jason J., et al.
Publicado: (2020)

Multigene prognostic tests in breast cancer: past, present, future
por: Győrffy, Balázs, et al.
Publicado: (2015)

A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients
por: Pongor, Lőrinc, et al.
Publicado: (2015)

Transient metabolic improvement in obese mice treated with navitoclax or dasatinib/quercetin
por: Sierra-Ramirez, Arantzazu, et al.
Publicado: (2020)

Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent
por: Mohamad Anuar, Nur Najmi, et al.
Publicado: (2020)

Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers
por: Li, Xiaotong, et al.
Publicado: (2021)

Synergism of a novel MCL-1 downregulator, acriflavine, with navitoclax (ABT-263) in triple-negative breast cancer, lung adenocarcinoma and glioblastoma multiforme
por: Lee, Anbok, et al.
Publicado: (2021)

Melatonin Can Modulate the Effect of Navitoclax (ABT-737) in HL-60 Cells
por: Lomovsky, Alexey, et al.
Publicado: (2020)

Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma
por: Langendonk, Myra, et al.
Publicado: (2022)

Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples
por: Fu, Chunxiao, et al.
Publicado: (2021)

Galacto‐conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity
por: González‐Gualda, Estela, et al.
Publicado: (2020)

Navitoclax combined with Alpelisib effectively inhibits Merkel cell carcinoma cell growth in vitro
por: Chteinberg, Emil, et al.
Publicado: (2020)

Selective Targeting of Cancer-Associated Fibroblasts by Engineered H-Ferritin Nanocages Loaded with Navitoclax
por: Sitia, Leopoldo, et al.
Publicado: (2021)

Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia
por: Johansson, Kimberly B., et al.
Publicado: (2023)

Diverse immune response of DNA damage repair-deficient tumors
por: Qing, Tao, et al.
Publicado: (2021)

CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax
por: Kour, Smit, et al.
Publicado: (2019)

Antagonizing the spindle assembly checkpoint silencing enhances paclitaxel and Navitoclax-mediated apoptosis with distinct mechanistic
por: Henriques, Ana C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2f5l24l9mrj3rijk1fcr6tj1bf